Cholangiocarcinoma

The combination of tislelizumab, lenvatinib, and gemcitabine/oxaliplatin was shown to be promising as a conversion therapy for patients with potentially resectable locally advanced biliary tract cancer in this phase 2 study.
Read More

Study revealed increased financial toxicities in patients with cholangiocarcinoma enrolled in clinical trials and receiving targeted therapies.
Read More

Erdafitinib was found to be associated with durable efficacy and manageable toxicity in Asian patients with advanced cholangiocarcinoma with FGFR alterations.
Read More

Study finds laparoscopic liver resection was associated with less blood loss and shorter length of stay compared with open liver resection.
Read More

Study found lower rates of margin-positive resection of intrahepatic cholangiocarcinoma with neoadjuvant chemotherapy.
Read More

Neoadjuvant chemoradiation was found to elicit no differences in survival among patients with unresectable perihilar cholangiocarcinoma.
Read More

A single-institution study found that liver-directed radiation therapy was associated with favorable tumor-related liver failure and survival times in patients with metastatic intrahepatic or extrahepatic cholangiocarcinoma.
Read More

Investigators found the addition of toripalimab to a gemcitabine-based chemotherapy regimen as first-line treatment of advanced biliary tract cancers demonstrated encouraging efficacy.
Read More

The phase 2 STAMP study revealed negligible differences in disease-free survival and overall survival between adjuvant gemcitabine/cisplatin versus capecitabine in lymph node–positive extrahepatic cholangiocarcinoma but found increased grade 3/4 adverse events with gemcitabine/cisplatin.
Read More

A systematic review of phase 2 and 3 clinical trials for biliary tract cancers revealed quality-of-life assessments were not routinely included as trial outcomes.
Read More

Page 4 of 14


Subscribe Today!

To sign up for our newsletter or print publications, please enter your contact information below.

I'd like to receive: